Adaptimmune Therapeutics (ADAP)
| Bid | 0.2 |
| Market Cap | 56.9M |
| Revenue (ttm) | 178.03M |
| Net Income (ttm) | -70.81M |
| EPS (ttm) | -0.28 |
| PE Ratio (ttm) | -0.79 |
| Forward PE | -1.24 |
| Analyst | Buy |
| Ask | 0.24 |
| Volume | 1,534,667 |
| Avg. Volume (20D) | 1,692,069 |
| Open | 0.24 |
| Previous Close | 0.21 |
| Day's Range | 0.20 - 0.23 |
| 52-Week Range | 0.20 - 1.48 |
| Beta | 2.84 |
About ADAP
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa...
Analyst Forecast
According to 5 analyst ratings, the average rating for ADAP stock is "Buy." The 12-month stock price forecast is $1.5, which is an increase of 574.76% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · seekingalpha.com
Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call TranscriptAdaptimmune Therapeutics plc (NASDAQ:ADAP ) Q4 2024 Earnings Conference Call March 20, 2025 8:00 AM ET Company Participants Juli Miller - IR Adrian Rawcliffe - CEO Cintia Piccina - Chief Commercial Of...
